Spherix Announces Results of Studies to Explore Sports and Nutrition/Nutraceutical Markets for D-tagatose

Spherix Announces Results of Studies to Explore Sports and 
Nutrition/Nutraceutical Markets for D-tagatose 
TYSONS CORNER, VA -- (Marketwired) -- 07/10/13 --   Spherix
Incorporated (NASDAQ: SPEX) -- an intellectual property development
company, earlier this year announced an agreement with ChromaDex,
Corp. (OTCQB: CDXC) to extend the commercial market for D-tagatose,
expand the structure function claims for the GRAS food ingredient,
and to optimize supply chain management for D-tagatose production. As
a result of this collaboration, ChromaDex delivered to Spherix a plan
to explore the expansion of D-tagatose into nutraceutical and sports
nutrition markets based on Spherix' technology during its drug
research phase. The clinical studies on D-tagatose that have been
completed by Spherix will provide a significant advantage, which
should allow for the introduction of a cost effective dietary
supplement ingredient with science backed health benefit claims. 
D-tagatose is a natural sweetener present in only small amounts in
fruits and dairy products, but it can be commercially produced
through an enzymatic process beginning with other natural sugars.
With the same bulk and sweetness of regular sugar (i.e., sucrose) and
no after-taste, D-tagatose is an ideal solution for sweet and savory
products. D-tagatose has a documented prebiotic effect and a low
caloric value of 1.5 kcal per gram. D-tagatose has a glycemic and
insulin index of only 3% of that of glucose.  
"Using the existing Spherix clinical study data should allow for
expansion of structure function claims for D-tagatose, which would
make it more valuable than a simple sweetener," stated Troy Rhonemus,
Director of New Technologies and Supply Chain Development at
Spherix has engaged ChromaDex to investigate the potential of
D-tagatose in the dietary supplement and sports nutrition markets and
granted an option to commercialize D-tagatose based products. 
About Spherix
 Spherix Incorporated was launched in 1967 as a
scientific research company. Spherix presently offers a diversified
commercialization platform for protected technologies. The company
continues to work on life sciences and drug development and presently
is exploring opportunities in sports and nutritional supplement
products rel
ying on its D-tagatose natural sweetener as a GRAS
ingredient. Spherix is committed to advancing innovation by active
participation in all areas of the patent market. Spherix draws on
portfolios of pioneering technology patents to partner with and
support product innovation. Through its recently announced
acquisition of several hundred patents issued to Harris Corporation
Spherix intends to expand its activities in wireless communications
and telecommunication sectors including antenna technology, Wi-Fi,
base station functionality, and cellular.  
About ChromaDex(R): 
  ChromaDex(R) is an innovative natural products
company that discovers, acquires, develops and commercializes
proprietary-based ingredient technologies through its unique business
model which utilizes its wholly-owned synergistic business units,
including ingredient technologies, natural product fine chemicals
(known as "phytochemicals"), chemistry and analytical testing
services, and product regulatory and safety consulting (as Spherix
Consulting). The Company provides seamless science-based solutions to
the dietary supplement, food & beverage, animal health, cosmetic and
pharmaceutical industries. Our ingredient technologies unit includes
products backed with extensive scientific research and intellectual
property. The ingredient portfolio includes pTeroPure(R)
pterostilbene; ProC3G(TM), a natural black rice containing
cyanidine-3-glucoside; PURENERGY(TM), a caffeine-pTeroPure
co-crystal; nutraGac(TM), a gac fruit powder; curcumin, and
nicotinamide riboside, a novel next-generation B-vitamin currently
under development. To learn more about ChromaDex please visit
Forward Looking Statements 
 Certain statements in this press release
constitute "forward-looking statements" within the meaning of the
federal securities laws. Words such as "may," "might," "will,"
"should," "believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking statements,
which are based on information available to us on the date of this
release. These forward looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including without limitation those set forth in the
Company's filings with the Securities and Exchange Commission (the
"SEC"), not limited to Risk Factors relating to its patent business
contained therein. Thus, actual results could be materially
different. The Company expressly disclaims any obligation to update
or alter statements whether as a result of new information, future
events or otherwise, except as required by law. 
Investor Relations 
Phone: (703) 992-9325 
Email: info@spherix.com 
Press spacebar to pause and continue. Press esc to stop.